Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis.

Chen B, Tao L, Tian M, Ji Z

Clinical nutrition ESPEN30 Jan 2025Cited by 6 (Europe PMC)

PMID39892787DOI10.1016/j.clnesp.2025.01.056PepBankPUB-39892787

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

01HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, adding semaglutide to basal insulin reduced HbA1c (mean difference -1.17%) in pooled trials.
In plain wordsIn adults with type 2 diabetes, semaglutide added to basal insulin lowered HbA1c in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 2,354
Comparator
Placebo or other active treatment
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c mean difference
−1.17%
semaglutide plus basal insulin
Source sentences
Summary
Compared to placebo or other active treatment, the addition of semaglutide to basal insulin demonstrated significant reductions in hemoglobin A1c (HbA1c) [mean differences (MD): -1.17 %, P < 0.00001]
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review and meta-analysis aimed to assess the efficacy and safety of the combined use of semaglutide and basal insulin in individuals diagnosed with type 2 diabetes mellitus (T2DM).
Summary · context
7 RCTs with 2354 patients were incorporated into the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3989278701
02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, adding semaglutide to basal insulin reduced body weight (mean difference -5.99 kg) in pooled trials.
In plain wordsIn adults with type 2 diabetes, semaglutide added to basal insulin lowered body weight in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 2,354
Comparator
Placebo or other active treatment
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight mean difference
−5.99 kg
semaglutide plus basal insulin
Source sentences
Summary
body weight [MD -5.99 kg, P < 0.00001]
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review and meta-analysis aimed to assess the efficacy and safety of the combined use of semaglutide and basal insulin in individuals diagnosed with type 2 diabetes mellitus (T2DM).
Summary · context
7 RCTs with 2354 patients were incorporated into the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3989278702
03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, adding semaglutide to basal insulin reduced fasting glucose (mean difference -1.08) in pooled trials.
In plain wordsIn adults with type 2 diabetes, semaglutide added to basal insulin lowered fasting blood sugar in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseFasting plasma glucose change
Study
n = 2,354
Comparator
Placebo or other active treatment
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
FPG mean difference
−1.08%
semaglutide plus basal insulin
Source sentences
Summary
fasting blood glucose (FPG) [MD -1.08 %, P < 0.00001]
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review and meta-analysis aimed to assess the efficacy and safety of the combined use of semaglutide and basal insulin in individuals diagnosed with type 2 diabetes mellitus (T2DM).
Summary · context
7 RCTs with 2354 patients were incorporated into the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3989278703
04HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In pooled trials, adding semaglutide to basal insulin did not significantly raise the risk of adverse events (RR 1.46).
In plain wordsIn pooled trials, semaglutide added to basal insulin did not clearly raise the overall risk of side effects.
Peptide
Semaglutide
Outcome
No significant changeAny adverse events
Study
n = 2,354
Comparator
Placebo or other active treatment
Analysis
Secondary
Outcome group
Adverse events · Whole body
Measurements
Adverse events RR
1.46 NA
semaglutide plus basal insulin
Source sentences
Summary
No evidence indicated a higher risk of adverse events [RR 1.46, P = 0.13].
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review and meta-analysis aimed to assess the efficacy and safety of the combined use of semaglutide and basal insulin in individuals diagnosed with type 2 diabetes mellitus (T2DM).
Summary · context
7 RCTs with 2354 patients were incorporated into the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3989278704
05HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In pooled trials, adding semaglutide to basal insulin increased nausea.
In plain wordsIn pooled trials, semaglutide added to basal insulin caused more nausea.
Peptide
Semaglutide
Outcome
IncreaseNausea
Study
n = 2,354
Comparator
Placebo or other active treatment
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
However, it did result in increased rates of gastrointestinal adverse events, including nausea, vomiting and diarrhea.
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review and meta-analysis aimed to assess the efficacy and safety of the combined use of semaglutide and basal insulin in individuals diagnosed with type 2 diabetes mellitus (T2DM).
Summary · context
7 RCTs with 2354 patients were incorporated into the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3989278705
06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In pooled trials, adding semaglutide to basal insulin increased vomiting.
In plain wordsIn pooled trials, semaglutide added to basal insulin caused more vomiting.
Peptide
Semaglutide
Outcome
IncreaseVomiting
Study
n = 2,354
Comparator
Placebo or other active treatment
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
However, it did result in increased rates of gastrointestinal adverse events, including nausea, vomiting and diarrhea.
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review and meta-analysis aimed to assess the efficacy and safety of the combined use of semaglutide and basal insulin in individuals diagnosed with type 2 diabetes mellitus (T2DM).
Summary · context
7 RCTs with 2354 patients were incorporated into the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3989278706
07HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In pooled trials, adding semaglutide to basal insulin increased diarrhoea.
In plain wordsIn pooled trials, semaglutide added to basal insulin caused more diarrhoea.
Peptide
Semaglutide
Outcome
IncreaseDiarrhoea
Study
n = 2,354
Comparator
Placebo or other active treatment
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
However, it did result in increased rates of gastrointestinal adverse events, including nausea, vomiting and diarrhea.
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review and meta-analysis aimed to assess the efficacy and safety of the combined use of semaglutide and basal insulin in individuals diagnosed with type 2 diabetes mellitus (T2DM).
Summary · context
7 RCTs with 2354 patients were incorporated into the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3989278707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.